FAQ Library

Karen P. Seiter, MD

FAQ Library published on March 27, 2015

Dr. Karen Seiter explains how to recognize treatment failure or treatment resistance in CML patients.

Neil P. Shah, MD, PhD

FAQ Library published on December 20, 2013 in Pharmacologic

Dr. Neil Shah discusses the efficacy and safety considerations of the non-kinase inhibitor omacetaxine.

Neil P. Shah, MD, PhD

FAQ Library published on November 22, 2013 in Pharmacologic

Dr. Neil Shah discusses the efficacy and safety considerations of bosutinib therapy.

Susan M. O'Brien, MD

FAQ Library published on November 22, 2013 in Assess & Monitor

Dr. Susan O'Brien discusses the roles of Sokal and Hansford risk calculations in prognosis and treatment.

Neil P. Shah, MD, PhD

FAQ Library published on October 18, 2013 in Pharmacologic

Dr. Neil Shah discusses the efficacy and safety considerations of dasatinib therapy.

Jorge Eduardo Cortes, MD

FAQ Library published on October 18, 2013 in Practice

Dr. Jorge Cortes defines chronic-phase CML.

Susan M. O'Brien, MD

FAQ Library published on September 20, 2013 in Practice

Dr. Susan O'Brien discusses the recommendations for monitoring a mutation analysis in CML.

Jorge Eduardo Cortes, MD

FAQ Library published on September 20, 2013 in Practice

Dr. Jorge Cortes discusses when you should switch to an alternative TKI.

Neil P. Shah, MD, PhD

FAQ Library published on August 23, 2013 in Pharmacologic

Dr. Neil Shah discusses the efficacy and safety considerations of nilotinib therapy.

Susan M. O'Brien, MD

FAQ Library published on August 23, 2013 in Practice

Dr. Susan O'Brien discusses the most recent updates to the NCCN Guidelines for CML.